Clinical Effects of Raloxifene Hydrochloride in Women ..
raloxifene 84449-90-1 Route Of Synthesis _ Synthetic …
Raloxifene had stronger positive stimulative effects on collagen biosynthesis, through different biochemical mechanisms, than estradiol in human skin fibroblasts and might reverse some of the postmenopausal changes in skin or connective tissue.
Synthesis and pharmacology of 2-alkyl raloxifene …
Increase of collagen synthesis induced by raloxifene may be activated by both estrogen receptor dependent and independent pathways such as up-regulation of estrogen receptors, up-regulation of IGF receptor, trans-criptional regulation of collagen genes by estrogen receptor-raloxifene complex, increasing of prolidase activity or finally by inhibition of MMP-9 expression.
Drug spotlight-Raloxifene « New Drug Approvals
In addition to having demonstrated its antifracture effect, raloxifene presents beneficial effects on lipid metabolism and breast tissue. It is capable of lowering LDL-cholesterol levels and increasing HDL-cholesterol ones [,] and it also appears to reduce the risk of invasive breast cancer [,]. Both effects increase the value of this drug, making it especially useful in women with osteopenia or postmenopausal osteoporosis with lipid alterations or breast cancer risk factors.
DailyMed - EVISTA- raloxifene hydrochloride tablet
Acording this analysis, severity of vertebral fractures at baseline was a stronger predictor of nonvertebral fracture risk than low BMD. This finding does not diminish the importance of mild vertebral fractures at baseline, but severe prevalent vertebral fractures are probably indicative of more significant architectural deterioration of bone that should be clinically addressed. In the small subgroup of women with severe baseline vertebral fractures in the MORE cohort, raloxifene significantly decreased the risk of subsequent nonvertebral fractures. Nevertheless authors pointed out that, although this analysis is helpful in understanding the effect of raloxifene on vertebral and nonvertebral fractures, the present data do not allow for a direct comparison of nonvertebral fracture efficacy of raloxifene with bisphosphonates and do not imply that raloxifene is an alternative to bisphosphonates for reducing the risk of nonvertebral fractures, especially of the hip.